CA3206971A1 - Peptide pour le traitement du cancer - Google Patents

Peptide pour le traitement du cancer Download PDF

Info

Publication number
CA3206971A1
CA3206971A1 CA3206971A CA3206971A CA3206971A1 CA 3206971 A1 CA3206971 A1 CA 3206971A1 CA 3206971 A CA3206971 A CA 3206971A CA 3206971 A CA3206971 A CA 3206971A CA 3206971 A1 CA3206971 A1 CA 3206971A1
Authority
CA
Canada
Prior art keywords
seq
peptide
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206971A
Other languages
English (en)
Inventor
Sergiy BORYSOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saint Leo University
Original Assignee
Saint Leo University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/215,845 external-priority patent/US20210230227A1/en
Application filed by Saint Leo University filed Critical Saint Leo University
Publication of CA3206971A1 publication Critical patent/CA3206971A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Est divulgué un peptide qui présente une séquence d'acides aminés choisie parmi SEQ ID NO : 22 ; SEQ ID NO : 23 ; SEQ ID NO : 24 ; SEQ ID NO : 25 ; SEQ ID NO : 26 ; SEQ ID NO : 27 ; SEQ ID NO : 28 ; SEQ ID NO : 29 ; SEQ ID NO : 30 ; SEQ ID NO : 31 ; SEQ ID NO : 32, SEQ ID NO : 33 ; SEQ ID NO : 34 ; SEQ ID NO : 35 ; SEQ ID NO : 36 ; SEQ ID NO : 37 ; SEQ ID NO : 38 ; SEQ ID NO : 39 ; SEQ ID NO : 40 ; SEQ ID NO : 41 ; SEQ ID NO : 42 ; SEQ ID NO : 43 et/ou SEQ ID NO : 44 ; et des peptides de rétro-inversion associés. Les peptides décrit dans la description peuvent être utilisés pour inhiber l'activité hélicase et traiter le cancer, tel que le cancer du foie, le cancer du poumon, le cancer du sein, le cancer du pancréas ou le cancer du cerveau.
CA3206971A 2021-03-29 2022-03-29 Peptide pour le traitement du cancer Pending CA3206971A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/215,845 2021-03-29
US17/215,845 US20210230227A1 (en) 2019-09-27 2021-03-29 Peptide for treating cancer
PCT/US2022/022363 WO2022212389A1 (fr) 2021-03-29 2022-03-29 Peptide pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3206971A1 true CA3206971A1 (fr) 2022-10-06

Family

ID=83456805

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206971A Pending CA3206971A1 (fr) 2021-03-29 2022-03-29 Peptide pour le traitement du cancer

Country Status (3)

Country Link
EP (1) EP4313101A1 (fr)
CA (1) CA3206971A1 (fr)
WO (1) WO2022212389A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228429D0 (en) * 2002-12-05 2003-01-08 Novartis Ag Organic compounds
WO2019204563A2 (fr) * 2018-04-20 2019-10-24 Saint Leo University Peptide cyclique pour traiter le cancer
WO2021041953A1 (fr) * 2019-08-30 2021-03-04 The Regents Of The University Of California Méthodologies de criblage de surexpression de fragments de gènes et utilisations associées

Also Published As

Publication number Publication date
EP4313101A1 (fr) 2024-02-07
WO2022212389A1 (fr) 2022-10-06

Similar Documents

Publication Publication Date Title
ES2341767T3 (es) Quimioterapia de combinacion con clorotoxina.
EP2613808B1 (fr) Traitements du cancer d'animaux de compagnie avec des anticorps anti p2x7
WO2012112690A2 (fr) Ciblage de médicaments thérapeutiques et d'agents diagnostiques employant des domaines de liaison au collagène
AU2002322192B2 (en) Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
CN105705160B (zh) Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
AU2002322192A1 (en) Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
AU2019264673A1 (en) Vaccine compositions and methods for restoring NKG2D pathway function against cancers
US9422352B2 (en) PTD-SMAD7 therapeutics
WO2015070031A1 (fr) Compositions et méthodes de traitement du mélanome
TW202034943A (zh) 補體抑制劑之神經疾病治療
CN109718363B (zh) 预防、缓解或治疗阿尔茨海默病的肽及其应用
US20140140926A1 (en) Novel Peptides and Methods Using Same
US20200276273A1 (en) Method for treating myeloid leukemia
US11597757B2 (en) Peptide for treating cancer
US20210230227A1 (en) Peptide for treating cancer
CA3206971A1 (fr) Peptide pour le traitement du cancer
US20150265572A1 (en) Injectable cancer compositions
JP2018538275A (ja) 中枢神経系疾患の鼻腔内治療に使用するためのｃｄｎｆまたはｍａｎｆを含む組成物
US20210077575A1 (en) Nanoparticles for the targeted delivery of therapeutic polypeptides
Esche et al. Immunostimulation by bacterial components: I. Activation of macrophages and enhancement of genetic immunization by the lipopeptide P3CSK4
WO2019028427A1 (fr) Procédés d'identification et de préparation d'agents pharmaceutiques pour activer le récepteur tie2
RU2470666C2 (ru) Фармацевтическая композиция для трансназального введения
RU2777504C2 (ru) Способы и композиции для лечения повреждения хряща и артрита
WO2017075661A1 (fr) Procédés et compositions pour le traitement d'une lésion du système nerveux central

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230731

EEER Examination request

Effective date: 20230731

EEER Examination request

Effective date: 20230731

EEER Examination request

Effective date: 20230731

EEER Examination request

Effective date: 20230731